Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated ...

John Kenney Jr., MD, Lifetime Achievement Award and Lectureship recipient Pearl E. Grimes, MD, FAAD, delivered a tribute to her predecessor as she discussed the history and advancements of vitiligo.

The Medicare Part D redesign under the Inflation Reduction Act (IRA) is also expected to hurt sales of Pfizer’s higher-priced drugs like Vyndaqel, Ibrance and Xeljanz in 2025. However ...

It will reach the market later this month with the task of taking on Pfizer’s first-to-market Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib), which are both approved for RA.

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Once billed as a future blockbuster and rival to big-selling JAK drugs like Pfizer’s Xeljanz (tofacitinib), Jyseleca was hit by a series of setbacks, including a decision by the FDA to reject it ...